Skip to main content

Table 2 Clinical characteristics of patients based on polyglutamylation status

From: Clinical significance of polyglutamylation in primary central nervous system lymphoma

  Polyglutamylation (n = 43) Non polyglutamylation (n = 39) p
Age (y)
 Median (range) 68 (37–84) 67 (46–86) 0.70*
Sex (# of pts)
 Male/ Female 27/ 16 19/ 20 0.20**
KPS (%)
 Median (range) 50 (20–100) 40 (20–100) 0.43*
(# of pts) High (≥70) / Low (≤60) 12/ 31 10/ 29 0.82**
MSKCC prognostic score
 Median (range) 3 (1–3) 3 (1–3) 0.76*
Cell of origin
 GCB/ non-GCB 17/ 24a 7/ 32 0.022**
LDH (# of pts)
 High/ Normal range 16/ 27 15/ 24 0.91**
Location (# of pts)
 Deep/ No 35/ 8 27/ 12 0.20**
  1. KPS Karnofsky performance status, pts. patients
  2. * Mann-Whitney U test
  3. ** Chi-squared test
  4. a data from two patients were not available